Please assess the completion status of the following clinical trial:

Trial Title: Clopidogrel Pharmacogenomics Project

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:• Currently taking clopidogrel 75 mg/day and aspirin (minimum 81 mg/day) with an indication for chronic dual antiplatelet therapy (\>90 days)~* No evidence of acute coronary syndrome within 30 days of enrollment, defined by elevation of Troponin I above the upper limit of normal~* Coronary atherosclerosis documented on previous coronary angiogram~* No known contraindications to combination therapy with aspirin and clopidogrel~* Prognosis for survival greater than one year based on physician's assessment~* Able to attend all scheduled visits.~* Access to phone~* Subject is a female with a negative urine or serum pregnancy test or post-menopausal for at least 1 year prior to randomization. Females of childbearing potential must be practicing adequate birth control to be eligible. It is the Investigator's responsibility for determining whether the Subject has adequate birth control for study participation~Exclusion Criteria:• Recent acute coronary syndrome (\<30 days)~* Recent hospitalization or physician visit for bleeding disorder(\<90 days) or history of chronic blood loss~* Recent blood transfusion (\<90 days)~* Any contraindication to aspirin or clopidogrel therapy~* Acute Febrile illness at the time of enrollment~* Subject is pregnant or lactating or planning to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 75 mg clopidogrel (Type: ACTIVE_COMPARATOR): None
- 150 mg clopidogrel (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).